

WPD Pharmaceuticals WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) is a clinical-stage pharmaceutical company, with a focus on glioblastoma cancer ("GBM") and other brain tumour programs.

It operates its business primarily through WPD Poland, a subsidiary of and the operating branch of the Company, WPD Pharmaceuticals Sp. z o.o.. The Company owns approximately 20% of the outstanding shares of WPD Poland.


Investment Theses

-  Licensing partnerships with Wake Forest University (US)
-  Global rights for WPD family of product
-  Robust drug portfolio
-  Experienced team
-  Financial leverage by grants

Key drug candidates

WPD101a/b, 103 family

A family of biopharmaceuticals in preclinical stages of development for targeted treatment of brain tumors with a global license. Recombinant IL-13 and ephrin 1 proteins armed with potent bacteria toxins or small molecules preferentially bind to tumor-specific receptors and deliver highly cytotoxic payload.



Berubicin -co-development

Berubicin is one of the first anthracyclines proven to cross the blood-brain barrier and able to reach brain tumors. In January 2023 WPD Pharmaceuticals started multicenter, open-label, Phase Ib/II clinical study of Berubicin in patients with recurrent glioblastoma multiforme (GBM). A previously conducted Phase I clinical study showed promising therapeutic effects in GBM patients with one complete response.

WPD will seek partners and investors, who could help in further development of WPD101a and other products that may be developed under the license agreement with Wake Forest University and plans to submit applications for new grants for further development of this line of product

Contact

 investors@wpdpharmaceuticals.com

 www.wpdpharmaceuticals.com

VIEW LEGAL DISCLAIMER AND FORWARD LOOKING STATEMENTS [HERE](#)